Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Convertible Debt (2025)

Valion Bio has reported Convertible Debt over the past 1 years, most recently at $6.5 million for Q4 2025.

  • For Q4 2025, Convertible Debt changed N/A year-over-year to $6.5 million; the TTM value through Dec 2025 reached $6.5 million, changed N/A, while the annual FY2025 figure was $6.5 million, N/A changed from the prior year.
  • Convertible Debt for Q4 2025 was $6.5 million at Valion Bio.
  • Over five years, Convertible Debt peaked at $6.5 million in Q4 2025 and troughed at $6.5 million in Q4 2025.